文献速递妇科

新辅助化疗后同源重组基因表达谱不同与卵巢癌患者临床结局相关

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-02-01

研究从96例高级别卵巢癌减瘤手术新鲜冷冻肿瘤样本(初治直接手术组55例、新辅助化疗后手术组41例)提取RNA,用定制NanoString泛癌通路面板分析19个同源重组基因表达与生存的关联。初治组6个同源重组基因过表达与结局改善相关,新辅助化疗组4个同源重组基因与结局变差相关;加入减瘤程度协变量后,初治组3个基因、新辅助化疗组仅RAD51仍与生存显著相关。结论认为不同同源重组表达谱可定义新辅助化疗暴露患者的结局亚组。

要点

  • 初治直接手术组中C11orf30、NBN、FANCF、FANCC、FANCB、RAD50过表达与结局改善相关。
  • 新辅助化疗组中BRCA2、TP53、FANCB、RAD51与结局变差相关。
  • 加入减瘤程度协变量后,初治组NBN、FANCF、RAD50及新辅助化疗组RAD51仍与生存显著相关。

核心结论

  • 不同的同源重组基因表达谱可定义新辅助化疗暴露患者中与总结局相关的亚组,而不仅限于未接受化疗的患者。

研究设计与样本

  • 从96例高级别卵巢癌减瘤手术新鲜冷冻肿瘤样本提取RNA,样本经妇科病理学家选择高肿瘤含量并用肿瘤含量百分比协变量及突变评分协变量分析确认。
  • 样本包括初治直接手术组55例和新辅助化疗后手术组41例,使用定制NanoString泛癌通路面板进行基因表达分析,采用Cox比例风险回归模型评估19个同源重组基因表达与生存的关联。

主要发现

  • 初治直接手术组中6个同源重组基因(C11orf30、NBN、FANCF、FANCC、FANCB、RAD50)过表达与结局改善相关。
  • 新辅助化疗组中4个同源重组基因(BRCA2、TP53、FANCB、RAD51)与结局变差相关。
  • 加入减瘤程度作为协变量后,初治直接手术组3个基因(NBN、FANCF、RAD50)仍与生存显著相关,新辅助化疗组仅RAD51仍与生存显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The expression of homologous recombination (HR) genes in high grade ovarian cancer (HGOC) samples from debulking surgeries were correlated to outcomes in patients selected for chemotherapy treatment regimens. STUDY DESIGN: RNA was extracted from 96 fresh frozen tumor samples from debulking surgeries from chemotherapy naïve patients with HGOC (primary derived surgeries (PDS), n = 55) or following neoadjuvant chemotherapy treatment (NACT), n = 41). The samples were selected for high tumor content by a gynecological pathologist, and cancer cell content was further confirmed using a percent tumor content covariate, and mutation score covariate analysis. Gene expression analysis was performed using a tailored NanoString-based Pancancer Pathway Panel. Cox proportional hazard regression models were used to assess the associations between the expression of 19 HR genes and survival. RESULTS: In the PDS group, over-expression of six HR genes (C11orf30, NBN, FANCF, FANCC, FANCB, RAD50) was associated with improved outcome, in contrast to the NACT group where four HR genes (BRCA2, TP53, FANCB, RAD51) were associated with worse outcome. With the adding extent of debulking as a covariate, three HR genes (NBN, FANCF, RAD50), and only one HR gene (RAD51) remained significantly associated with survival in PDS and NACT groups, respectively. CONCLUSION: Distinct HR expression profiles define subgroups associated with overall outcome in patients that are exposed to neoadjuvant chemotherapy and not only chemotherapy-naïve patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kessous R, Octeau D, Klein K, et al. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecol Oncol. 2018. PMID: 29395310. doi:10.1016/j.ygyno.2018.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。